130-26-7 Usage
Chemical Properties
Almost white, light yellow, brownish-yellow or yellowish-grey powder.
Originator
Clioquinol,CIBA-GEIGY Corp.
Uses
Different sources of media describe the Uses of 130-26-7 differently. You can refer to the following data:
1. Clioquinol is used as an anti-infective agent; antiamoebic agent; intravaginal trichomonacide; used to impregnate cotton bandages for antibacterial purposes; in animals as an intestinal anti-infective agent.
2. alpha adrenergic blocker, mydriatic, antidepressant
3. Used as a topical antifungal treatment
Definition
ChEBI: A monohydroxyquinoline that is quinolin-8-ol in which the hydrogens at positions 5 and 7 are replaced by chlorine and iodine, respectively. It has antibacterial and atifungal properties, and is used in creams for the treatment of skin infections. It has al
o been investigated as a chelator of copper and zinc ions for the possible treatment of Alzheimer's disease.
Indications
Iodochlorhydroxyquin (Clioquinol), containing 40% iodine, was originally developed
as a substitute for iodoform as an antiseptic dusting powder. Although its
most effective use is in the treatment of amebiasis, it also has mild antibacterial
and antifungal effects and may be used alone or with steroids in the treatment
of eczematous and impetiginized processes and some dermatophyte, yeast, and
Trichomonas infections. However, more specific agents are available. Because of
neurotoxicity, the oral form of this drug has been withdrawn in the United States.
A recent study demonstrating significant percutaneous absorption when applied to
intact human skin raises concern regarding its topical use as well. The medication
may stain the skin, hair, and clothing yellow and may induce contact allergy.
Manufacturing Process
Chlor-5-oxy-8-chinoline (18 kg) was mixed with potassium hydroxide (6.0 kg),
water (400 kg) and heated. To this solution 50 L saturated aqueous solution of
potassium iodide (16.6 kg) was added, mixed and continued to heat. Solution
was filtered at room temperature. Then to this yellow solution the solution of
chloride of lime and 50 kg 5% solution of were added then all this was mixed
and allowed to stand for 24 h.
After eliminating of free iodine by addition of sodium thiosulfate the obtained
precipitate was washed with water. To residue 1% solution of acidum
hydrochloricum (50.0 kg) and rapidly was heated to 50°C. Then it was washed
with water and dried, so 5-chloro-7-iodo-quinolinol-8 was obtained, melting
point 170°-175°C.
Brand name
Domeform-HC (Bayer); Quin-O-Creme
(Marion Merrell Dow); Rheaform Boluses [Veterinary]
(Fort Dodge Animal Health); Vioform (Ciba-Geigy);Amebio-formo;Anterobe;Aristoform "d";Aristoform "r";Barquinol hc;Betnorate-c;Britaderm;Britadex-vioform;Carboform;Cloro-yodo-hidroxi;Clorpine;Combias;Copover;Cortex;Corti-glottyl;Dependal;Dermo-quinol;Dermozolan;Dexalocal;Diaban;Dioderm c-c;Diodotracin;Dizenterol;Enteral;Ente-rivo;Enterokin;Enterosan;Entero-valodon;Entero-vioformo;Enterquinol;Entox;Entrasorb;Entrokinol;Fusalor-yodocloro;Fyloxxal;Gmd;Guanosept;Haelan-c;Hocacorten-vioform;Hydroform;Iodo-cortifair;Iodocortindon;Iodo-max;Isoderm;Khlorlinkotsin;Klinicin;Lecortin;Lederform-d;Lemoderm;Linola;Locorten-vioform;Metrijet;Metrityl;Mexafermento;Mexafom;Nasello;Nefurox;Obstecrim;Pedi-cort;Percural;Phen-ortis;Pricort cream;Propaderm-c;Quadriderm;Quin iii;Quina band;Quiniodochlor;Reticus;Sebryl;Sedacol;Septo-canulase;Silic c;Tequinophil;Toptic;Torofor;Unidiarea;Uteroject;Ventribex;Viform;Vioform bolus;Vioform hydrocortisan;Vioform hydrocortisone;Vioforme.
Therapeutic Function
Antibacterial
World Health Organization (WHO)
Clioquinol, a halogenated hydroxyquinoline derivative, was
introduced into medicine around 1900 as a topical antiseptic and in 1934 oral
preparations for the treatment of amoebic dysentery and simple diarrhoea became
available. By 1964 its use in Japan had been associated with cases of sub-acute
myelo-optic neuropathy (SMON) which reached epidemic proportions resulting in
its withdrawal there in 1970. Although relatively few cases of SMON were
documented elsewhere, clioquinol was subsequently withdrawn from use in many
countries and placed under prescription control in others. It was phased out
worldwide by the major manufacturer between 1983 and 1985 on grounds of
obsolescence. No adequately controlled evidence was ever generated to
demonstrate that clioquinol is effective in bacterial or viral diarrhoea. However,
products containing clioquinol and related halogenated hydroxyquinolines
continue to be used in some tropical and subtropical countries where amoebiasis
remains endemic. Other amoebocides are preferred in the WHO Model List of
Essential Drugs.
(Reference: (WHODI) WHO Drug Information, 77.1, 9, 1977)
General Description
Cream-colored to brownish-yellow powder. Practically odorless. Decomposes at 178-179°C. Used as a topical anti-infective.
Air & Water Reactions
Insoluble in water.
Reactivity Profile
Clioquinol is incompatible with strong oxidizing agents, strong acids, acid chlorides and acid anhydrides . Darkens on exposure to light.
Fire Hazard
Flash point data for Clioquinol are not available; however, Clioquinol is probably combustible.
Flammability and Explosibility
Nonflammable
Clinical Use
5-Chloro-7-iodo-8-quinolinol, 5-chloro8-hydroxy-7-iodoquinoline, or iodochlorhydroxyquin (Vioform) occursas a spongy, light-sensitive, yellowish white powder that isinsoluble in water. Vioform was initially used as a substitutefor iodoform in the belief that it released iodine in the tissues.It has been used as a powder for many skin conditions,such as atopic dermatitis, eczema, psoriasis, and impetigo.A 3% ointment or cream has been used vaginally as a treatmentfor Trichomonas vaginalis vaginitis. The best use forVioform is in the topical treatment of fungal infections suchas athlete’s foot and jock itch. A combination with hydrocortisone(Vioform HC) is also available.
Safety Profile
Poison by ingestion.
Moderately toxic by intraperitoneal route.
Human systemic effects by ingestion:
change in central nervous system electrical
function, optic nerve damage, and changes
in vision. Experimental teratogenic and
reproductive effects. Human mutation data
reported. When heated to decomposition it
emits very toxic fumes of Cl-, I-, and NOx.
Purification Methods
It crystallises from AcOH or xylene and dry it at 70o in vacuo.[Beilstein 21 III/IV 1190.]
Check Digit Verification of cas no
The CAS Registry Mumber 130-26-7 includes 6 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 3 digits, 1,3 and 0 respectively; the second part has 2 digits, 2 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 130-26:
(5*1)+(4*3)+(3*0)+(2*2)+(1*6)=27
27 % 10 = 7
So 130-26-7 is a valid CAS Registry Number.
InChI:InChI=1/C10H6ClIO/c11-8-5-9(12)10(13)7-4-2-1-3-6(7)8/h1-5,13H
130-26-7Relevant articles and documents
One-pot method for preparing chloroquine chloroquine and diiodoquinoline
-
, (2021/08/25)
The method effectively solves the problems of (1) solving the problem of high isomer ratio in reaction products due to the fact that hydroxyl groups are ortho-alignment positioning groups when no guide groups are first C5 halogenated and C7 iodo, and purification difficulty is also increased. (2) The problems of poor atom economy, harsh reaction conditions, tedious aftertreatment steps and the like in first 66% steps C5 C7 C7 are effectively overcome by the method provided by the invention, and the C5-position halogenated product is 60% effectively overcome by overcoming the defects of poor atom economy, harsh reaction conditions, complicated post-treatment steps and the like in the two methods. The method has the advantages of economy of atoms, simplicity in operation, easiness in amplification and the like.
NOVEL RECYCLABLE IODINATING AGENT AND ITS APPLICATIONS
-
Page/Page column 19-20, (2016/11/07)
The present invention provides a novel recyclable catalysts of formula A, [Formula A should be inserted here] wherein X is selected from the group consisting of [Formula should be inserted here] The present invention also provides a novel recyclable iodinating agent of formula I, II or III and a process for the synthesis thereof. [ Formula I, II & III should be inserted here] Further, the present invention provides a process of halogenation of amines and heterocyclic compounds by employing recyclable catalyst of formula (I).
Aza-and polyaza-naphthalenly ketones useful as hiv integrase inhibitors
-
Page/Page column 45, (2010/02/10)
Certain aza- and polyaza-naphthalenyl ketones including certain quinolinyl and naphthyridinyl ketones are described as inhibitors of HIV integrase and inhibitors of HIV replication. These compounds are useful in the prevention or treatment of infection by HIV and the treatment or the delay in the onset of AIDS, as compounds or pharmaceutically acceptable salts, or as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of treating or delaying the onset of AIDS and methods of preventing or treating infection by HIV are also described.